Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chongqing Genrix Biopharmaceutical Co (SHSE:688443) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Chongqing Genrix Biopharmaceutical Co PS Ratio Related Terms
Chongqing Genrix Biopharmaceutical Co PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chongqing Genrix Biopharmaceutical Co PS Ratio Chart
SHSE:688443 vs VRTX, REGN, MRNA: PS Ratio Comparison
For the Biotechnology subindustry, Chongqing Genrix Biopharmaceutical Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chongqing Genrix Biopharmaceutical Co PS Ratio vs Biotechnology Industry
Chongqing Genrix Biopharmaceutical Co PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Chongqing Genrix Biopharmaceutical Co's Share Price of today is ¥23.36. Chongqing Genrix Biopharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.92.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Chongqing Genrix Biopharmaceutical Co (SHSE:688443) has a PS Ratio of 25.31 as of Sep. 02, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Chongqing Genrix Biopharmaceutical Co and its competitors. This is 92% below median its historical median of 306.95. Over the past decade, Chongqing Genrix Biopharmaceutical Co's PS Ratio has ranged from 24.07 to 20,130.00. According to the industry distribution chart, Chongqing Genrix Biopharmaceutical Co ranks #651 out of 937 companies in the Biotechnology industry, placing it in the top 69.5%.
Is Chongqing Genrix Biopharmaceutical Co's PS Ratio too high?
Chongqing Genrix Biopharmaceutical Co's current PS Ratio of 25.31 is 92% below median its 10-year median of 306.95. Over the past 10 years, this metric has ranged from a low of 24.07 to a high of 20,130.00. The Biotechnology industry median PS Ratio is 9.54. Chongqing Genrix Biopharmaceutical Co's value of 25.31 is 165.3% above this industry median. Based on the distribution chart, Chongqing Genrix Biopharmaceutical Co ranks #651 out of 937 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Chongqing Genrix Biopharmaceutical Co has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Chongqing Genrix Biopharmaceutical Co's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chongqing Genrix Biopharmaceutical Co ranks #651 out of 937 companies for PS Ratio. This places Chongqing Genrix Biopharmaceutical Co in the lower half of its industry. The industry median PS Ratio is 9.54. Chongqing Genrix Biopharmaceutical Co's value of 25.31 is 165.3% above this benchmark. Historically, Chongqing Genrix Biopharmaceutical Co's own PS Ratio has ranged from 24.07 to 20,130.00 over the past decade. While the company's 10-year median is 306.95 vs. the industry median of 9.54, Chongqing Genrix Biopharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.54, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chongqing Genrix Biopharmaceutical Co's current PS Ratio of 25.31 is 165.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Chongqing Genrix Biopharmaceutical Co and its competitors. For the Biotechnology industry, the median PS Ratio is 9.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chongqing Genrix Biopharmaceutical Co's current PS Ratio is 25.31, which is 92% below median its own 10-year median of 306.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chongqing Genrix Biopharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chongqing Genrix Biopharmaceutical Co (SHSE:688443) is currently considered Possible Value Trap. The stock's GF Value™ is ¥284.88, compared to a current price of ¥23.36 — trading 91.8% below its estimated fair value. The current PS Ratio is 25.31, which is 92% below median its 10-year median of 306.95 and 165.3% above the Biotechnology industry median of 9.54. Chongqing Genrix Biopharmaceutical Co's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Chongqing Genrix Biopharmaceutical Co (SHSE:688443), the current PS Ratio is 25.31 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Overvalued in 2026?
Based on GuruFocus' analysis, Chongqing Genrix Biopharmaceutical Co stock appears to be undervalued.
The current stock price of ¥23.36 is trading 91.8% below its estimated GF Value™ of ¥284.88.
GuruFocus considers Chongqing Genrix Biopharmaceutical Co to be Possible Value Trap.
Key valuation signals for SHSE:688443:
PS Ratio: 25.31 (92% below median its 10-year median of 306.95)
GF Value™: ¥284.88 vs. price of ¥23.36 (91.8% below fair value)
Industry Position: 165.3% above the Biotechnology median (#651 of 937)
No single metric tells the full story. See the SHSE:688443 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chongqing Genrix Biopharmaceutical Co Ltd is a biopharmaceutical company engaged in the research & development, production and sales of antibody drugs. The company's pipeline includes product candidate that targets Autoimmune Diseases, Infectious Diseases, and Oncology.
65GF Score
Get the complete analysis for SHSE:688443
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688443 has been successfully added to your 
